menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Omega-3 Fatty Acids and ASCVD

What’s the role of omega-3 fatty acids in treating patients with or at high risk of atherosclerotic cardiovascular disease (ASCVD)?

Live Broadcast
Information
May 14, 2020
12:00 PM - 01:00 PM EDT
Online
Omega-3 Fatty Acids and ASCVD
Choose a format
Details
Presenters
Related
Comments
  • Overview

    During this interactive and engaging activity, we will focus on addressing the role of omega-3 fatty acids in treating patients with or at high risk of atherosclerotic cardiovascular disease (ASCVD) using the most recent evidence and guideline recommendations.

  • ProgramSchedule

    Welcome, Introductions, Program Overview
    Dave L. Dixon, PharmD - Chair

    15 minutes

    Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD
    Joseph Saseen, PharmD

    15 minutes

    Comparisons of Omega-3 Fatty Acid Products
    Daniel E. Hilleman, PharmD

    15 minutes

    Clinical Utility of Adjunct Therapies to Statins for ASCVD Event Reduction
    Dave L. Dixon, PharmD - Chair

    15 minutes

    Discussion, Questions and Answers
    All Faculty

    Closing Comments, Adjourn
    Dave L. Dixon, PharmD - Chair

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Describe the spectrum of large-scale omega-3 fatty acids on ASCVD outcomes trials
    • Recognize the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Use information on clinical utility of adjuncts to statin therapy to improve management of patients with or at high risk of ASCVD events
  • Target Audience

    This activity is designed to meet the educational needs of retail, hospital and managed care pharmacists.

  • Accreditation and Credit Designation Statements

    Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    UAN: 0430-9999-20-002-L01-P
    Credits: 1.0  (0.10 CEU) for this CE activity
    Type of Activity: Application

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

Facebook Comments

Details
Presenters
Related
Comments
Recommended
  • Overview

    During this interactive and engaging activity, we will focus on addressing the role of omega-3 fatty acids in treating patients with or at high risk of atherosclerotic cardiovascular disease (ASCVD) using the most recent evidence and guideline recommendations.

  • ProgramSchedule

    Welcome, Introductions, Program Overview
    Dave L. Dixon, PharmD - Chair

    15 minutes

    Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD
    Joseph Saseen, PharmD

    15 minutes

    Comparisons of Omega-3 Fatty Acid Products
    Daniel E. Hilleman, PharmD

    15 minutes

    Clinical Utility of Adjunct Therapies to Statins for ASCVD Event Reduction
    Dave L. Dixon, PharmD - Chair

    15 minutes

    Discussion, Questions and Answers
    All Faculty

    Closing Comments, Adjourn
    Dave L. Dixon, PharmD - Chair

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Describe the spectrum of large-scale omega-3 fatty acids on ASCVD outcomes trials
    • Recognize the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Use information on clinical utility of adjuncts to statin therapy to improve management of patients with or at high risk of ASCVD events
  • Target Audience

    This activity is designed to meet the educational needs of retail, hospital and managed care pharmacists.

  • Accreditation and Credit Designation Statements

    Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    UAN: 0430-9999-20-002-L01-P
    Credits: 1.0  (0.10 CEU) for this CE activity
    Type of Activity: Application

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 11/30/20